Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
N. A. Shah
19576  Ergebnisse:
Personensuche X
?
1

MICROFLUIDIC SEPARATION TECHNOLOGY IMPROVES PURITY AND YIEL..:

Song, H.W. ; Underwood, S. ; Traynor, R....
Cytotherapy.  26 (2024)  6 - p. S26 , 2024
Link: https://doi.org/10.1016/..
 
?
2

SINGLE-CELL TRANSCRIPTOME ANALYSIS REVEALS DISTINCT CHARACT..:

Shao, L. ; Shi, R. ; Cai, Y....
Cytotherapy.  26 (2024)  6 - p. S12-S13 , 2024
Link: https://doi.org/10.1016/..
 
?
3

BISPECIFIC ANTI‐CD20/19 CAR‐T—ZAMTOCABTAGENE AUTOLEUCEL FOR..:

Ulrickson, M. ; Miklos, D. B. ; Maziarz, R. T...
Hematological Oncology.  41 (2023)  S2 - p. 147-147 , 2023
Link: https://doi.org/10.1002/..
 
?
4

HIGH COMPLETE RESPONSE RATE WITH TNB‐486, A NOVEL CD19XCD3 ..:

Cho, S. ; Nair, R. ; Jacobs, R....
Hematological Oncology.  41 (2023)  S2 - p. 127-129 , 2023
Link: https://doi.org/10.1002/..
 
?
5

Process Development and Manufacturing: CAR-T CELLS MANUFACT..:

Song, H.W. ; Benzaoui, M. ; Underwood, S....
Cytotherapy.  25 (2023)  6 - p. S9 , 2023
Link: https://doi.org/10.1016/..
 
?
6

LISOCABTAGENE MARALEUCEL (LISO‐CEL) IN R/R CHRONIC LYMPHOCY..:

Siddiqi, T. ; Maloney, D. G. ; Kenderian, S. S....
Hematological Oncology.  41 (2023)  S2 - p. 60-62 , 2023
Link: https://doi.org/10.1002/..
 
?
7

GENOMIC EVOLUTION AND RESISTANCE TO PIRTOBRUTINIB IN COVALE..:

Patel, K. ; Brown, J. R. ; Desikan, S. P....
Hematological Oncology.  41 (2023)  S2 - p. 185-187 , 2023
Link: https://doi.org/10.1002/..
 
?
8

Brentuximab vedotin (BV) + AVD for newly diagnosed classic ..:

Bowers, J. T. ; Anna, J. ; Bair, S. M....
Hematological Oncology.  41 (2023)  S2 - p. 359-360 , 2023
Link: https://doi.org/10.1002/..
 
?
9

Long‐term safety with ≥12 months of pirtobrutinib in relaps..:

Wang, Y. ; Coombs, C. C. ; Shah, N. N....
Hematological Oncology.  41 (2023)  S2 - p. 480-481 , 2023
Link: https://doi.org/10.1002/..
 
?
10

Health‐related quality of life in patients with relapsed or..:

Maloney, D. G. ; Siddiqi, T. ; Fakhri, B....
Hematological Oncology.  41 (2023)  S2 - p. 538-541 , 2023
Link: https://doi.org/10.1002/..
 
?
11

PIRTOBRUTINIB IN COVALENT BTK‐INHIBITOR PRE‐TREATED MANTLE ..:

Cheah, C. Y. ; Shah, N. N. ; Jurczak, W....
Hematological Oncology.  41 (2023)  S2 - p. 153-156 , 2023
Link: https://doi.org/10.1002/..
 
?
12

P1101: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REV..:

Eyre, T. A. ; Wang, M. L. ; Shah, N. N....
HemaSphere.  6 (2022)  - p. 991-992 , 2022
Link: https://doi.org/10.1097/..
 
?
13

P640: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVE..:

Roeker, L. E. ; Mato, A. R. ; Brown, J. R....
HemaSphere.  6 (2022)  - p. 538-539 , 2022
Link: https://doi.org/10.1097/..
 
?
14

S147: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVE..:

Mato, A. R. ; Pagel, J. M. ; Coombs, C. C....
HemaSphere.  6 (2022)  - p. 48-49 , 2022
Link: https://doi.org/10.1097/..
 
?
15

Shorter Interval between Treatment and COVID Immunization I..:

Mohan, Meera ; Nagavally, Sneha ; Shah N, Nirav N...
Clinical Lymphoma Myeloma and Leukemia.  22 (2022)  7 - p. e495-e497 , 2022
Link: https://doi.org/10.1016/..
 
1-15